Amgen Inc. (NASDAQ:AMGN) Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 2.5% during the first quarter, Holdings Channel reports. The institutional investor owned 24,060 shares of the medical research company’s stock after selling 610 shares during the period. E. Ohman J or Asset Management AB’s holdings in Amgen were worth $7,496,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Centricity Wealth Management LLC acquired a new stake in shares of Amgen during the fourth quarter worth about $25,000. Pinney & Scofield Inc. acquired a new stake in shares of Amgen during the fourth quarter worth about $26,000. Ritter Daniher Financial Advisory LLC DE increased its position in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock worth $33,000 after purchasing an additional 51 shares in the last quarter. Synergy Investment Management LLC acquired a new stake in shares of Amgen during the fourth quarter worth about $34,000. Finally, Atala Financial Inc acquired a new stake in shares of Amgen during the fourth quarter worth about $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Johnson Rice set a $294.00 target price on Amgen in a research report on Wednesday, March 5th. Mizuho boosted their price target on Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research report on Wednesday, May 7th. Piper Sandler dropped their price target on Amgen from $329.00 to $328.00 and set an “overweight” rating on the stock in a research report on Friday, May 16th. Wall Street Zen upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 18th. Finally, Erste Group Bank cut Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $309.22.

Amgen Trading Up 0.0%

Shares of Amgen stock opened at $287.10 on Friday. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm has a market cap of $154.38 billion, a PE ratio of 38.03, a P/E/G ratio of 2.63 and a beta of 0.51. The business’s fifty day moving average is $281.91 and its two-hundred day moving average is $285.36. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same quarter in the prior year, the company posted $3.96 EPS. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.